Table 2.
Summary of univariable Cox regression analyses of expression levels of candidate genes in breast carcinomas associated with progression-free survival (PFS) without regard to ER or PR status
| Gene symbol | β | HR | 95% CI (HR) | p value | Adjusted p value |
|---|---|---|---|---|---|
| Methylxanthine alkaloid receptors | |||||
| ADORA1 | 0.08 | 1.08 | (0.93, 1.25) | 0.325 | 0.772 |
| ADORA2A | 0.00 | 1.00 | (0.84, 1.20) | 0.976 | 0.976 |
| ADORA2B | 0.06 | 1.06 | (0.93, 1.20) | 0.382 | 0.772 |
| ADORA3 | 0.01 | 1.01 | (0.83, 1.22) | 0.949 | 0.976 |
| DRD2 | 0.11 | 1.11 | (0.95, 1.30) | 0.195 | 0.748 |
| CACNA1S | 0.11 | 1.11 | (0.83, 1.49) | 0.478 | 0.786 |
| RYR1 | − 0.05 | 0.96 | (0.76, 1.20) | 0.696 | 0.942 |
| SPECC1L | − 0.11 | 0.90 | (0.64, 1.26) | 0.529 | 0.811 |
| Phosphodiesterases | |||||
| PDE1A | 0.17 | 1.19 | (1.02, 1.38) | 0.025 | 0.289 |
| PDE1B | 0.23 | 1.26 | (0.92, 1.71) | 0.149 | 0.748 |
| PDE1C | 0.30 | 1.35 | (0.75, 2.45) | 0.321 | 0.772 |
| PDE3A | 0.21 | 1.23 | (0.31, 4.88) | 0.765 | 0.976 |
| PDE4A | − 0.29 | 0.75 | (0.63, 0.89) | 0.001 | 0.016 |
| PDE4B | 0.00 | 1.00 | (0.89, 1.13) | 0.939 | 0.976 |
| PDE5A | − 0.13 | 0.87 | (0.62, 1.22) | 0.434 | 0.772 |
| Enzymes metabolizing methylxanthines | |||||
| CYP1A2 | − 0.03 | 0.97 | (0.38, 2.48) | 0.951 | 0.976 |
| CYP2A6 | − 0.07 | 0.93 | (0.81, 1.07) | 0.312 | 0.772 |
| CYP3A4 | − 0.13 | 0.88 | (0.63, 1.22) | 0.436 | 0.772 |
| CYP2C8 | − 0.10 | − 0.90 | (0.78, 1.05) | 0.169 | 0.748 |
| CYP2C9 | 0.04 | 1.04 | (0.76, 1.41) | 0.809 | 0.976 |
| CYP2E | − 0.18 | 0.83 | (0.69, 1.00) | 0.049 | 0.379 |
| NAT2 | − 0.03 | 0.97 | (0.85, 1.11) | 0.667 | 0.942 |
| XDH | − 0.07 | 0.93 | (0.80, 1.09) | 0.380 | 0.772 |
Genes with expression levels that were significant at a discovery cutoff and adjusted p value < 0.30 are shown in bold